Nobody Wants to Be Narcan\u27d: A Pilot Qualitative Analysis of Drug Users\u27 Perspectives on Naloxone by Lai, Jeffrey T. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Publications by UMMS Authors 
2021-02-08 
Nobody Wants to Be Narcan'd: A Pilot Qualitative Analysis of Drug 
Users' Perspectives on Naloxone 
Jeffrey T. Lai 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Emergency Medicine Commons, Health Services Administration Commons, and the 
Substance Abuse and Addiction Commons 
Repository Citation 
Lai JT, Goldfine CE, Chapman BP, Taylor MM, Rosen RK, Carreiro S, Babu KM. (2021). Nobody Wants to Be 
Narcan'd: A Pilot Qualitative Analysis of Drug Users' Perspectives on Naloxone. Open Access Publications 
by UMMS Authors. https://doi.org/10.5811/westjem.2020.10.48768. Retrieved from 
https://escholarship.umassmed.edu/oapubs/4623 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access 
Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, 
please contact Lisa.Palmer@umassmed.edu. 
UC Irvine
Western Journal of Emergency Medicine: Integrating Emergency 
Care with Population Health
Title






















eScholarship.org Powered by the California Digital Library
University of California
Volume 22, no. 2: March 2021 339 Western Journal of Emergency Medicine
Original research
 
Nobody Wants to Be Narcan’d: A Pilot Qualitative Analysis of 
Drug Users’ Perspectives on Naloxone
 
Jeffrey T. Lai, MD*
Charlotte E. Goldfine, MD†
Brittany P. Chapman, BSc*
Melissa M. Taylor, BA*
Rochelle K. Rosen, PhD‡
Stephanie P. Carreiro, MD*
Kavita M. Babu, MD*
Section Editor: Erik S. Anderson, MD                
Submission history: Submitted June 16, 2020; Revision received September 25, 2020; Accepted October 29, 2020 
Electronically published February 8, 2021  




Bystander naloxone distribution is an evidence-
based public health intervention.1,2 The Surgeon General 
of the United States has emphasized the importance of 
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Introduction: Bystander naloxone distribution is an important component of public health initiatives 
to decrease opioid-related deaths. While there is evidence supporting naloxone distribution 
programs, the effects of increasing naloxone availability on the behavior of people who use drugs 
have not been adequately delineated. In this study we sought to 1) evaluate whether individuals’ 
drug use patterns have changed due to naloxone availability; and 2) explore individuals’ knowledge 
of, access to, experiences with, and perceptions of naloxone. 
Methods: We conducted a pilot study of adults presenting to the emergency department whose 
medical history included non-medical opioid use. Semi-structured interviews were conducted with 
participants and thematic analysis was used to code and analyze interview transcripts.  
Results: Ten participants completed the study. All were aware of naloxone by brand name (Narcan) 
and had been trained in its use, and all but one had either currently or previously possessed a kit. 
Barriers to naloxone administration included fear of legal repercussions, not having it available, 
and a desire to avoid interrupting another user’s “high.” Of the eight participants who reported 
being revived with naloxone at least once during their lifetime, all described experiencing a noxious 
physical response and expressed a desire to avoid receiving it again. Furthermore, participants did 
not report increasing their use of opioids when naloxone was available.
Conclusions: Participants were accepting of and knowledgeable about naloxone, and were willing 
to administer naloxone to save a life. Participants tended to use opioids more cautiously when 
naloxone was present due to fears of experiencing precipitated withdrawal. This study provides 
preliminary evidence countering the unsubstantiated narrative that increased naloxone availability 
begets more high-risk opioid use and further supports increasing naloxone access. [West J Emerg 
Med. 2021;22(2)339-345.] 
the opioid overdose reversal agent, stating succinctly and 
unambiguously, “knowing how to use naloxone and keeping 
it within reach can save a life.”3 However, efforts to enhance 
naloxone availability have been hampered by stigma 
surrounding opioid use disorder (OUD), cost and availability 
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Population Health Research Capsule
What do we already know about this issue?
Bystander naloxone is an evidence-based 
public health intervention. Increasing naloxone 
availability is a cornerstone of efforts to 
combat opioid overdose deaths.
What was the research question?
How is bystander naloxone perceived by opioid 
users? Has naloxone availability affected 
opioid use behaviors?
What was the major finding of the study?
Participants were familiar with naloxone 
and did not report increased opioid use when 
naloxone was available.
How does this improve population health?
This study affirms that bystander naloxone 
is acceptable to its intended audience and 
suggests that naloxone availability does not 
increase high-risk opioid use.
issues, and the unproven assertion that naloxone increases 
high-risk drug use.4-7 To evaluate perceptions of naloxone 
uptake and use in our population, we piloted a semi-structured 
interview developed in conjunction with the National Drug 
Early Warning System (NDEWS) workgroup.8 
Importance
Although studies have demonstrated that increased 
availability of naloxone has reduced the rate of opioid 
overdose fatalities in some communities, there is a paucity of 
data on whether it has also impacted drug use behaviors. Data 
regarding knowledge of and attitudes toward naloxone among 
people who use drugs (PWUD), and the impact of naloxone 
availability on drug-use behaviors, are urgently needed. In 
this pilot study, we explored the knowledge and perceptions 
of naloxone among PWUD in order to obtain more nuanced 
data to guide public health interventions aimed at decreasing 
opioid overdose deaths.
Goals of This Investigation
This study sought to 1) explore individuals’ knowledge 
of, access to, experiences with, and perceptions of naloxone; 
and 2) characterize reported changes in individuals’ drug use 
patterns and attitudes as a result of naloxone accessibility. 
METHODS
Study Design and Setting
This pilot study was part of a larger multisite effort by 
the NDEWS workgroup to validate a qualitative interview 
agenda regarding knowledge and perceptions of bystander 
naloxone among PWUD. During the trial period (March-
April 2019), we enrolled a convenience sample of 10 adult 
patients who presented to the University of Massachusetts 
Memorial Medical Center emergency department (ED) 
with an opioid-related chief complaint (eg, drug overdose, 
cutaneous abscess, etc) and history of non-medical opioid 
use. Among the three sites in the study, ours was distinct in 
that we focused on individuals who presented for evaluation 
in the emergency care setting rather than in an outpatient 
clinic. This protocol was approved by the University of 
Massachusetts Medical School Institutional Review Board. 
A Certificate of Confidentiality was obtained to provide an 
additional layer of participant protection.
Selection of Participants
Study investigators screened the electronic health record 
ED tracking board for individuals meeting inclusion criteria 
and approached them once they were deemed medically 
stable by the provider overseeing their clinical care. Eligible 
participants were 18-65 years of age, had presented to the 
ED with an opioid-related chief complaint, had a history 
of non-medical opioid use, were English-speaking, and 
were able to provide informed consent. Individuals were 
excluded if they had previously participated in this study or 
were in police custody. A study investigator obtained verbal 
informed consent from participants, who were brought to 
a private room in the ED for the duration of the interview. 
Participants were compensated for their time with a $10 gift 
card to a local retail store. 
Interventions
Two investigators were present during study interviews, 
with one taking the lead role as facilitator and the other 
functioning as a notetaker. Investigators administered a 
brief questionnaire regarding demographic characteristics, 
as well as a semi-structured interview developed by 
the NDEWS workgroup, which contained open-ended 
questions regarding naloxone. A written agenda was used to 
guide each interview, ensuring that the same key questions 
were asked of all participants. This allowed each individual 
to answer in his/her own words, and to describe relevant 
experiences. The agenda included questions about access 
to, knowledge of, attitudes about, and experiences with 
naloxone, as well as each participant’s prior history of 
drug overdose. Participants were asked to respond based 
on their own thoughts and experiences, as well as provide 
insight on their perceptions of what other people who use 
opioids think about naloxone, and whether the availability 
of naloxone has changed how other users conceptualize 
drug use. 
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Analysis 
We tabulated and entered demographic data into Research 
Electronic Data Capture (REDCap), a secure web-based 
application for building and managing online surveys and 
databases.9,10 Semi-structured interviews were audio-recorded 
on a digital voice recorder and transcribed by trained study 
staff or by a transcription service compliant with the Health 
Insurance Portability and Accountability Act. Study staff 
reviewed each transcription to ensure accuracy and to 
deidentify qualitative data.  
Two researchers (BC and MT) independently coded 
the first two transcripts, creating deductive codes based 
on questions in the semi-structured qualitative agenda and 
inductive codes for emergent topics raised by participants. The 
initial codes were reviewed by the research team, resulting in 
a preliminary thematic coding scheme. This framework was 
applied to all transcripts, which were independently coded 
by both researchers (BC and MT). New codes were created 
as needed when adjustments were made to accommodate 
topics in subsequently coded transcripts, which were then 
retroactively applied to initially coded transcripts as well. 
Upon completion of independent coding, both researchers met 
to review differences in coding, which were discussed and 
refined until agreement between the researchers was reached. 
After five interviews no further changes were made to the 
codes. We entered the agreed-upon codes into NVivo 12 Plus 
(QSR International, Burlington, MA) to complete the thematic 
analysis, and then reviewed them in aggregate to create 
summaries of key topic areas.  
RESULTS
A total of 28 individuals were screened for recruitment 
during the study period. Of those, 12 were unable to be 
enrolled as they either eloped (n = 4), were unable to provide 
consent (n = 1), had no non-medical opioid use in the prior six 
months (n = 6), or reason was not documented (n = 1). Of the 
16 potential participants who were approached, six declined 
to participate in the study: three identified as female and three 
as male, and ages ranged from 28-35 years with a median age 
of 32 years. Ten participants were enrolled in this study; the 
demographics of the study participants are detailed in Table 
1. The sample was predominantly young, White males who 
had been in treatment for OUD on at least one occasion. The 
majority had previously received naloxone. The sample varied 
on education, employment, and housing status.
Analysis of semi-structured interviews revealed several 
themes, which are described in detail below. Additional 
illustrative quotations are included for each theme (Table 2).
Familiarity with Narcan (mechanism and use) 
All participants were familiar with the brand name 
“Narcan,” but some were not familiar with the generic term 
“naloxone.” One individual mistook naloxone for naltrexone. 
A single participant had never heard the term “naloxone” 
before. All participants reported having formal naloxone 
training from sites including local treatment facilities and 
harm-reduction organizations. Most reported first hearing 
about naloxone through treatment programs (eg, detox, 
Alcoholics Anonymous meetings) or correctional facilities, 
from other people who use opioids for non-medical purposes, 
and from occasions where they had received it for overdose 
reversal. Two participants informed study staff that they could 
not recall how they first learned about naloxone because they 
had “known about it for so long.” 
Most participants understood the general purpose of 
naloxone to be reversing an opioid overdose, yet there were 
varying degrees of knowledge about the exact underlying 
mechanisms. The majority of participants used specific 
terminology implying blockade or antagonism when 
describing how naloxone works (eg, “receptor,” “blocker,” 
and “reversant”). Most participants identified naloxone’s 
specificity for opioids, but there were two participants who 
also questioned its utility for other substances, such as alcohol. 
All but one participant reported that they currently or 
previously possessed a naloxone kit. Of those nine, three 
participants reported that their reasoning for carrying a kit was 
to save the lives of others. One participant stated, “If someone 
needed it, I would rather have it than be powerless.” The 
majority of participants reported obtaining naloxone kits that 
contained the newer, “easy” plunger-style nasal spray. Three 
participants mentioned that they had previously obtained the 
more “difficult to use” older version that required assembly. 
Naloxone Is Available and Easy to Obtain
Participants universally agreed that naloxone kits were 
available and easy to obtain from a variety of organizations 
(eg, pharmacies, treatment facilities). All participants knew 
the process for obtaining a naloxone kit, and several reported 
obtaining it from a harm-reduction agency (eg, needle 
exchange) that distributed it for free and provided training. 
When asked how programs that distribute naloxone could 
improve their services, some participants suggested increasing 
access by providing naloxone kits by default whenever 
someone visits a needle exchange or leaves a treatment 
program, and by implementing mobile programs of outreach 
workers to distribute it within the community. 
Naloxone Availability Is Viewed Positively
Participants perceived naloxone as a life-saving drug 
and were thankful for its presence in the community. One 
participant stated, “[I] think it’s an amazing drug. I’ve seen 
it save people’s lives.” Some participants reported feeling 
empowered by carrying naloxone and said they would use it to 
revive someone. When asked how individuals who had been 
revived by naloxone were perceived by other people who use 
opioids, many participants responded by saying they were 
“lucky.” Some participants stated that they themselves felt 
lucky after being revived with naloxone.
Western Journal of Emergency Medicine 342 Volume 22, no. 2: March 2021
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N=10




Race and ethnicity, N
White, neither Hispanic nor Latino 8
Native Hawaiian or other Pacific 
Islander, Hispanic or Latino
1
Multiracial, neither Hispanic nor Latino 1
Married or have significant other, N
Yes 5
No 5




Highest level of education completed, N
Less than high school 1
High school diploma or equivalent 1
Some college, no degree 5
Associate degree 3





Employed full-time and student 1
Retired/disabled 3





Sober living house 2
Chief complaint for this ED visit, N
Suspected opioid overdose, naloxone 
administered
4
Other opioid-related chief complaint 6
Received naloxone (lifetime), N
Yes 8
No 2




Table 1. Participant demographics.
N=10







Naloxone Produces Aversive Symptoms During Reversal
All participants who had previously been revived with 
naloxone reported experiencing extraordinarily unpleasant 
physical responses consistent with severe opioid withdrawal 
(eg, nausea, vomiting, diffuse body pain). One participant 
described it as the worst pain he had ever experienced. When 
these participants were asked about their emotional response, 
several disclosed that they felt embarrassed or experienced 
feelings of depression and anxiety regarding their return to opioid 
use. Participants acknowledged that receiving naloxone was an 
experience that they would go to great lengths to avoid. However, 
in the event that they were to overdose and require naloxone to 
save their life, they hoped someone would administer it. 
Availability of Naloxone Does Not Increase Risky Drug-
use Behavior 
Participants were unanimous that their decision to use 
opioids did not depend on naloxone availability. While 
participants speculated vaguely that a hypothetical “other” 
group of people who use opioids might adopt riskier drug 
use behavior due to the availability of naloxone (such as 
taking bigger doses or using more often), all participants 
explicitly denied that they themselves engaged in riskier 
behavior and/or increased their opioid use in any way due 
to the availability of naloxone. Several participants reported 
that they had recently experienced a return-to-use event, but 
none identified naloxone availability as playing any role in 
this occurrence. 
Several participants stated that they had heard of or had 
seen others using heroin/fentanyl immediately after being 
revived with naloxone to mitigate withdrawal symptoms. One 
participant reported doing this herself, while simultaneously 
noting that this was “messed up.” Participants reported that 
people are using in groups as a harm reduction strategy and 
likened using alone to a death sentence.
Barriers to Carrying Naloxone Are Primarily Related to 
Potential Social and Legal Consequences
Participants described several potential barriers when 
speculating why an individual might choose not to administer 
naloxone: fear of legal repercussions; not having naloxone 
available at that moment; and not wanting to interrupt the 
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individual’s euphoric experience (“high”). Interestingly, 
some participants felt that having naloxone on their person 
would be perceived by other people as an admission that their 
recovery might not be successful, and that this decreased their 
desire to carry it. Of note, two participants expressed concern 
that carrying naloxone might be interpreted specifically by 
authority figures (eg, parole officers) as a return to drug use, 
which would potentially result in legal repercussions. None of 
the participants had ever self-administered naloxone or knew 
of anyone who had; all believed that it was impossible or very 
difficult to do so when indicated. 
Good Samaritan laws, which vary by state, protect 
individuals from prosecution for drug possession if they seek 
emergency services assistance for a suspected overdose.11 
Nine participants expressed some understanding of the 
Good Samaritan Law in Massachusetts, but there was 
variable comprehension about what this law covers. Several 
participants also expressed concern over whether law 
enforcement agencies would adhere to these laws. 
Additional Novel Findings
Most participants shared the belief that the majority/all 
of the current “heroin” supply in their community is actually 
fentanyl, and that obtaining “real heroin” was a difficult thing 
to do. Fentanyl was reportedly less desirable because it was 
perceived as more dangerous and shorter-acting than heroin, 
requiring more frequent dosing. Most participants identified 
cyanosis as the major indicator differentiating the desired 
opioid effect from an overdose. These participants described 
the presence of a skin “color change” to blue as the signal to 
administer naloxone.
DISCUSSION
Our participants were familiar with and accepting of 
naloxone. They were also willing to administer this medication 
to someone who had overdosed. However, participants 
tended to rely upon the presence of cyanosis, a late finding in 
overdose, as the indication for naloxone administration. Despite 
a willingness to carry and use naloxone, we found that some 
Theme Quotes
Familiarity with Narcan (mechanism and use) “[Narcan] basically pulls the opiate out of the receptor.”
“[Narcan is] a reversant of heroin overdose.”
“I want to help others; I’m not walking around with [Narcan] just for the hell of it; I’m 
gonna try to save a life.”
Naloxone is available and easy to obtain “I get [Narcan] for free, I never paid one dollar for it. There’s plenty of programs that 
give it out for free.”
“[Narcan]’s not hard to get, so no excuse. Nothing to prevent them from getting it.”
Naloxone availability is viewed positively “[I] think [Narcan is] an amazing drug. I seen it save people’s lives.”
“You could probably walk to the corner and you always see someone out [overdosed]...
If someone needed [Narcan], I would rather have it than be powerless.”
“[Narcan is] the best tool to have.  It’s the best tool to use.”
Naloxone produces aversive symptoms 
during reversal
“Nobody wants to be Narcan’d.”
“[Receiving Narcan feels like] instant withdrawal, but the worst withdrawal you ever 
felt in your life. Like you feel like your legs are broken, your head’s screaming.”
“[Receiving Narcan is] kind of embarrassing and degrading and you know it’s upsetting.”
“[When receiving Narcan for an overdose], it’s better to feel the pain than die.”
The availability of naloxone does not increase 
risky drug use behavior
“It’s not like we use heroin because we have naloxone...I’ve never seen anyone that 
wouldn’t already do heroin, do heroin because they have naloxone.”
“Maybe people are using [heroin] more in groups now because obviously they’re not 
going to administer naloxone on their dead body.”
Barriers to carrying naloxone are primarily 
related to potential social and legal 
consequences
“Trust me, the cops don’t follow the Good Samaritan law. They don’t have to...They’re 
supposed to, but it doesn’t mean they do.”
• Knowledge of Good Samaritan Laws “It’s if-if you get caught with somebody, if-if they’re both high and you... are using 
[drugs], and he is using, [the police] can’t arrest you.”
• Barriers to reviving others “Say you needed Narcan, and I was gonna be the one to give it, maybe I’d be 
hesitant ‘cause I’m like, ‘I don’t know, I don’t wanna ruin his high.’”
“[After giving someone Narcan,] now you have someone who’s sick who wants your 
dope... So they’re not highly regarded.”
Table 2. Illustrative comments from study participants.
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participants associated possession of naloxone with feelings 
of weakness or potential failure. We found that participants 
denied engaging in riskier opioid use behaviors when naloxone 
was available. In fact, some individuals who had previously 
overdosed and received naloxone held such a strong aversion 
to the experience of precipitated opioid withdrawal that they 
reported subsequently using less drug to decrease their overdose 
risk. Although our data set was small, we did establish thematic 
saturation for a preliminary study with respect to the question of 
whether naloxone facilitated riskier drug use: Our participants 
were unanimous in reporting that they did not decide to use 
opioids nor increase their opioid use because of increased 
naloxone availability.
Previous studies have indicated that non-opioid users 
hold overall positive opinions of naloxone.12-14 A survey of 
lay persons found that while only 61% of respondents had 
heard of naloxone, most respondents (88%) felt naloxone was 
beneficial in preventing accidental opioid overdoses.12 Both 
medical professionals and state government agencies support 
efforts to increase naloxone availability due to demonstrated 
benefits in reducing opioid overdose mortality.15,16 However, 
an oft-repeated criticism of naloxone distribution efforts lies 
in the idea that naloxone availability enables individuals to use 
opioids without the fear of death, thereby encouraging high-
risk drug use behaviors.17 A majority of the lay public felt that 
naloxone was only necessary for people who misuse opioids, 
and that the availability of naloxone enabled these individuals 
to increase their opioid use.12 Lay media reports have 
perpetuated the idea of “Narcan parties” or “Lazarus parties,” 
where people intentionally use large amounts of opioid to 
overdose with the expectation that they will subsequently be 
revived by naloxone administration.4,5 
Despite the persistence of these views in popular opinion, 
our data and the available literature contradict the supposition 
that enhanced availability of naloxone leads to increased 
opioid use.1,4,18 Our participants reported no increase in their 
drug use in spite of widespread availability of naloxone. 
Instead, they actively attempted to avoid naloxone reversal 
due to the associated adverse effects and were somewhat 
reluctant to administer it to others unless they were sure 
they needed it. Although our sample is small, it consists of a 
relatively experienced group of people who use opioids, as 
evidenced by prior treatment attempts for OUD and number of 
drug-related ED visits. Our preliminary finding that this group 
did not report adopting riskier drug-use patterns in the context 
of increased naloxone availability suggests that proliferation 
of bystander naloxone programs does not beget increased 
opioid use.
Overall, many of our participants had a high degree of 
functional knowledge regarding naloxone, held a generally 
positive view of naloxone, and expressed a willingness to 
administer naloxone when necessary. Despite traumatic 
experiences associated with receiving naloxone, participants 
perceived naloxone as a life-saving medication. Contrary 
to the popular belief that individuals increase their drug use 
when naloxone is available, some participants reported that 
they used less opioids to avoid being administered naloxone. 
Additionally, our participants described using in groups as a 
contingency plan to mitigate the risk of overdose, and do not 
view naloxone as a facilitator of riskier drug use. 
Our results suggest several areas that can be targeted to 
enhance public health interventions. There was widespread 
thought among participants that the presence of cyanosis 
(“color change”) in an individual is the primary indicator 
of overdose and the need for naloxone administration. 
Future naloxone education efforts targeted to PWUD, as 
well as the lay public, should stress that cyanosis is a late 
finding and emphasize indicators that differentiate “high” 
from overdose, such as shallow or slowed breathing. Our 
participants suggested that visits to needle exchanges 
and discharges from treatment programs are high-value 
times to ensure that PWUD are equipped with naloxone. 
Furthermore, they identified mobile outreach programs as a 
desirable community-based harm-reduction service. Public 
health initiatives should also work to address concerns that 
carrying naloxone may signal unsuccessful recovery, and 
instead rebrand bystander naloxone as a willingness to save 
others’ lives. It may further be beneficial to increase public 
awareness that naloxone is not for self-administration.   
LIMITATIONS
The limitations of this pilot study include a small sample 
size (n = 10) and the fact that it was conducted in a single 
community where several groups were over-represented (eg, 
male, White, prior naloxone resuscitation, prior treatment 
for OUD). Although our study population was fairly 
homogenous and not representative of PWUD on a national 
scale, it is a typical sample for PWUD in our region in terms 
of demographics and experience with drug use. We did not 
appreciate a difference in characteristics between approached 
vs enrolled patients. Nevertheless, this may detract from 
generalizability to other settings where the demographics may 
differ and individuals may have cultural differences or less 
familiarity with opioid use, opioid antagonists, and treatment 
modalities for OUD. 
That our study was conducted in an urban ED at the 
epicenter of the North American opioid epidemic likely does 
skew our study population to favor individuals with more 
experience and health literacy surrounding their substance use 
disorder, as evidenced by a majority having previously received 
naloxone for overdose reversal and treatment for OUD. 
Furthermore, our state government’s progressive response to 
the opioid epidemic likely enhances our PWUD population’s 
familiarity with naloxone. Additionally, although all study staff 
are trained in qualitative interview techniques, inadvertent use 
of leading questions could have led to interviewer bias. 
Since the data were analyzed by the qualitative interviewers, 
there was no ability to blind the coders. This could have resulted 
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in bias when assigning the thematic codes, which is why two 
independent reviewers coded the data and analysis was reviewed 
by all researchers. Moreover, we were unable to administer 
the interview in languages other than English, resulting in the 
exclusion of several individuals who were otherwise eligible 
for participation. Finally, our study used self-report of an illegal 
and stigmatized behavior, rather than direct observations of how 
naloxone availability affected drug use behaviors; the results may 
therefore be influenced by recall bias and social desirability bias. 
These factors limit the generalizability of our findings to other 
demographic groups and locales. 
CONCLUSION
We found that participants were accepting of, knowledgeable 
about, and willing to use naloxone. Furthermore, we discovered 
that participants did not increase their use of opioids when 
naloxone was available, but rather tended to use opioids more 
cautiously due to fears of experiencing precipitated withdrawal 
from naloxone administration. These findings further support the 
need for increasing access of naloxone to help prevent opioid 
overdose deaths.
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